Viking TherapeuticsVKTX
VKTX
About: Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
Employees: 36
0
Funds holding %
of 7,419 funds
0
Analysts bullish %
of 8 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
80% more call options, than puts
Call options by funds: $296M | Put options by funds: $164M
15% more repeat investments, than reductions
Existing positions increased: 145 | Existing positions reduced: 126
6% less first-time investments, than exits
New positions opened: 81 | Existing positions closed: 86
1.09% less ownership
Funds ownership: 74.59% [Q3] → 73.51% (-1.09%) [Q4]
3% less funds holding
Funds holding: 418 [Q3] → 404 (-14) [Q4]
36% less capital invested
Capital invested by funds: $5.17B [Q3] → $3.3B (-$1.87B) [Q4]
75% less funds holding in top 10
Funds holding in top 10: 8 [Q3] → 2 (-6) [Q4]
Research analyst outlook
8 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$30
26%
upside
Avg. target
$79
234%
upside
High target
$125
427%
upside
8 analyst ratings
6 positive
75%
2 neutral
25%
0 negative
0%
HC Wainwright & Co. Joseph Pantginis 14% 1-year accuracy 59 / 417 met price target | 330%upside $102 | Buy Reiterated | 17 Apr 2025 |
Goldman Sachs Richard Law 50% 1-year accuracy 4 / 8 met price target | 26%upside $30 | Neutral Initiated | 8 Apr 2025 |
Scotiabank George Farmer 19% 1-year accuracy 4 / 21 met price target | 330%upside $102 | Sector Outperform Initiated | 13 Feb 2025 |
Citigroup David Lebowitz 42% 1-year accuracy 8 / 19 met price target | 60%upside $38 | Neutral Initiated | 7 Feb 2025 |
Maxim Group Naz Rahman 0% 1-year accuracy 0 / 12 met price target | 195%upside $70 | Buy Maintained | 7 Feb 2025 |
Financial journalist opinion
Based on 24 articles about VKTX published over the past 30 days
Neutral
See It Market
6 hours ago
Is Viking Therapeutics Stock (VKTX) Nearing A Bottom?
With earnings scheduled for the 23rd, Viking Therapeutic's (NASDAQ: VKTX) first-quarter investor call is expected to center around key pipeline updates. The spotlight will be on three clinical candidates: VK2735 (targeting obesity), VK2809 (for non-alcoholic steatohepatitis, or NASH), and VK0214 (for X-linked adrenoleukodystrophy, or X-ALD).
Positive
Zacks Investment Research
4 days ago
Viking Therapeutics, Inc. (VKTX) Beats Stock Market Upswing: What Investors Need to Know
The latest trading day saw Viking Therapeutics, Inc. (VKTX) settling at $23.94, representing a +1.44% change from its previous close.
Neutral
The Motley Fool
4 days ago
2 Stocks Down by 25% or More This Year to Buy and Hold
Equity markets have had a rough go of it this year due to President Trump's macroeconomic policies. Though it can be challenging to navigate this environment, one way to make the best of it is to look for terrific stocks to invest in while they are down.
Positive
Seeking Alpha
4 days ago
Viking Therapeutics: A Lot More Compelling After The Meltdown - Initiating Cautious Buy (Rating Upgrade)
VKTX's deep selloff from the 2024 heights have been well warranted indeed, given its pre-revenue status and ongoing cash burn, despite the promising GLP-1 candidates. It has also triggered the improved margin of safety and relatively compelling 2030 valuations, despite the recently downgraded forward estimates. This is significantly aided by the improved clarity surrounding VKTX's go-to-market strategy, as the management announces its first supply and manufacturing partnership.
Positive
MarketBeat
5 days ago
Viking Therapeutics Stock Pops But Struggles to Hold Gains
Viking Therapeutics Inc. NASDAQ: VKTX has taken investors on a wild ride since the beginning of 2024. At one point, VKTX stock was up 375% from its closing price on January 2, 2024.
Neutral
Seeking Alpha
6 days ago
Viking Therapeutics: Trading The Volatility Of The Weight Loss Drug Market
Viking Therapeutics, Inc. stock has dropped ~35% amid market volatility, but Pfizer's withdrawal of danuglipron boosts VK2735's prospects as a leading oral GLP-1 for obesity. Goldman Sachs' Neutral rating highlights risks like high entry barriers, competition, and potential need for additional financing, impacting VK2735's commercial viability. Despite strong Phase II data, VK2735 faces competition from innovative obesity treatments, and strategic partnerships or buyouts could be crucial for Viking's success.
Neutral
Invezz
6 days ago
Will Pfizer approach Viking Therapeutics with a buyout proposal?
Investors are running into Viking Therapeutics (NASDAQ: VKTX) this week after an incident of drug-induced liver injury pushed Pfizer (NYSE: PFE) into terminating the development of its weight-loss pill.
Positive
Seeking Alpha
6 days ago
Viking Therapeutics' VK2735 Candidate Likely Boosted By Pfizer's Woes
13-week data from the Viking Therapeutics, Inc. phase 2 VENTURE-Oral Dosing trial using oral VK2735 for the treatment of patients with obesity, expected 2nd half of 2025. Pfizer's recent setbacks in weight-loss drugs may prompt it to consider acquiring VKTX, adding VK2735 and VK2809 to its pipeline. VK2735's dual administration routes and dual GLP-1/GIP agonist mechanism position it as a strong contender in the growing $37.94 billion anti-obesity market.
Positive
Zacks Investment Research
6 days ago
NVO, LLY, GPCR & VKTX Stocks Gain Following PFE's Obesity Study Setback
Shares of Novo Nordisk, Eli Lilly, Structure Therapeutics and Viking Therapeutics gain as PFE abandons development of its obesity candidate, danuglipron, due to safety issues.
Neutral
The Motley Fool
6 days ago
Down 71%, Should You Buy the Dip on Viking Therapeutics Stock?
No one ever claimed investing in the biotech industry was a smooth ride, but for shareholders of Viking Therapeutics (VKTX -1.14%), the turbulence has been extremely challenging thus far. The stock is down 71% over the past year, amid ongoing uncertainties regarding the timeline for future commercialization of its clinical pipeline and the broader stock market sell-off.
Charts implemented using Lightweight Charts™